{"id":1021277,"date":"2026-11-16T08:40:44","date_gmt":"2026-11-16T13:40:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/"},"modified":"2026-11-16T08:40:44","modified_gmt":"2026-11-16T13:40:44","slug":"in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/","title":{"rendered":"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Median progression-free survival (mPFS) of 13.0 months, nearly doubled the 6.6 months observed in the SOC control group<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Favorable safety profile with no observed cytokine release syndrome (CRS), ICANS, major infections or treatment-related serious adverse events with up to six repeat doses of gamma-delta T cells<\/em>\n      <\/p>\n<p>NEW YORK, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma (GBM), presented in an oral session at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia.<\/p>\n<p>The updated results demonstrated consistent survival outcomes among patients receiving repeat doses of IN8bio\u2019s drug-resistant \u03b3\u03b4 T cells. Across the INB-200 and INB-400 studies, patients receiving repeat doses of therapy achieved a final mOS of 20.9 months (+59%) and mPFS of 13.0 months (+97%), compared to 13.2 months and 6.6 months, respectively, in those receiving the SOC. Notably, 50% of patients receiving repeat-dose therapy (7 of 14) were alive at two years, compared with 10% of patients (1 of 10) in the group receiving only SOC. These outcomes were observed despite a lower proportion of repeat-dose patients having undergone total surgical resection.<\/p>\n<p>Importantly, \u03b3\u03b4 T cell therapy demonstrated a favorable safety and tolerability profile across the clinical studies, with no observed CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), major infections or treatment-related serious adverse events. No treatment-related deaths were reported.<\/p>\n<p>\u201cThese final updated results provide continued evidence of the potential for \u03b3\u03b4 T cell therapies to drive activity and improve outcomes for patients,\u201d said William Ho, CEO and co-founder of IN8bio. \u201cThe clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence of \u03b3\u03b4 T cells in patients receiving multiple doses. Importantly, across our clinical experience, we have not observed any CRS, ICANS, major infections or treatment-related serious adverse events. These data continue to underscore the potential of \u03b3\u03b4 T cell-based therapies to provide meaningful clinical benefit for patients.\u201d<\/p>\n<p>\n        <strong>Updated Clinical Results Presented at SNO 2026<\/strong>\n      <\/p>\n<p>The results were presented on Saturday, November 14, 2026 during the Clinical Trials Oral Abstracts Session II of the Society for Neuro-Oncology Annual Meeting in a presentation titled, \u201c<em>INB-200\/400: Final Phase 1\/2 Study Results and A.I. based Deep Correlative Analysis of Gene-Modified Autologous Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma (GBM) Patients<\/em>.\u201d<\/p>\n<p>The analysis included 17 patients treated with INB-200 or INB-400 across four leading cancer centers: the University of Alabama at Birmingham (UAB) O\u2019Neal Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Moffitt Cancer Center and the Cleveland Clinic.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:40%;width:40%;min-width:40%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">\n            <strong>Treatment Arm<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Median PFS<\/strong><br \/>\n            <br \/>\n            <strong>(months)<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Median OS<\/strong><br \/>\n            <br \/>\n            <strong>(months)<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"max-width:20%;width:20%;min-width:20%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>Patients Alive at<\/strong><br \/>\n            <br \/>\n            <strong>Two Years (%)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Historical NEJM Data<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">6.9<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">14.6<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle;border-right: solid black 1pt;vertical-align: middle\">26.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">Control (SOC) Patients<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">6.6<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">13.2<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(1\/10) 10%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">INB-200 DL1 Patients<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">8.0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">15.7<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(0\/3) 0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">INB-200 Repeat Dose Patients<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">16.1<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">21.1<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(5\/10)* 50%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">INB-400 Repeat Dose Patients<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">13.0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">20.9<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(2\/4) 50%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle\">All Repeat Dose Patients<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">13.0<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">20.9<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">(7\/14) 50%<\/td>\n<\/tr>\n<\/table>\n<p>Note: As of October 30, 2026. *Patients 007 and 014 passed away from cardiovascular events without progression. Patients without progression who are no longer alive are not censored in this analysis. Early trial results are not indicative of future results, including the outcome of this trial.<\/p>\n<p>Total surgical resection was performed in 43% of repeat-dose patients, compared with 80% of SOC control patients.<\/p>\n<p>\n        <strong>About IN8bio<\/strong>\n      <\/p>\n<p>IN8bio is a clinical-stage biopharmaceutical company developing \u03b3\u03b4 T cell and \u03b3\u03b4 T cell engager (TCE) product candidates to address unmet medical needs. \u03b3\u03b4 T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company\u2019s pipeline is anchored by INB-600, a novel \u03b3\u03b4 T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also developing INB-100, an allogeneic \u03b3\u03b4 T cell therapy candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200\/400, an autologous genetically modified \u03b3\u03b4 T cell therapy candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xQoVrA78xXRwuWbftTeAKb8G9znroYFBvrBi5JtViK-pb4B1WOX29KbT0TcDzF2MNnT-ELQ02lt2YSVSl0uFAw==\" rel=\"nofollow\" target=\"_blank\">www.in8bio.com<\/a>.<\/p>\n<p>\n        <strong>Investors and Corporate Contact:<\/strong>\n      <\/p>\n<p>IN8bio, Inc.<br \/>Patrick McCall<br \/>646.933.5603<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aSILiAVNU8jYtoqSSp04Ypo6kOZYSrf4sjSh0qVrW9Gg7snVq8Y9GHrbjY4yq8aSTEEMMLCG07PY-Dv7DUktcz_VPR4pbSl0jZ9vHeGyRHk=\" rel=\"nofollow\" target=\"_blank\">pfmccall@in8bio.com<\/a><\/p>\n<p>Media Contact<br \/>Kimberly Ha<br \/>KKH Advisors<br \/>917.291.5744<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4-9t6df8deMpG9Ds3-RfxVlbJpAmJ6Htt2oqZyoZ6mxjMV_1zuxvYeCyYQZkSN_yvZB33Hv7AF4NtvApTLOJvXkixJdMFKQCtYUJug5bwynj92J9sH32ZZbT6hvf2LOC\" rel=\"nofollow\" target=\"_blank\">kimberly.ha@kkhadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWFiMDMzMGEtYWNiOS00MmJjLTkxOTgtMzY2NjJjNzRkYjZhLTExMzQ1NzctMjAyNi0xMS0xNi1lbg==\/tiny\/IN8bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0 months, nearly doubled the 6.6 months observed in the SOC control group Favorable safety profile with no observed cytokine release syndrome (CRS), ICANS, major infections or treatment-related serious adverse events with up to six repeat doses of gamma-delta T cells NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021277","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0 months, nearly doubled the 6.6 months observed in the SOC control group Favorable safety profile with no observed cytokine release syndrome (CRS), ICANS, major infections or treatment-related serious adverse events with up to six repeat doses of gamma-delta T cells NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated &hellip; Continue reading &quot;IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T13:40:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy\",\"datePublished\":\"2026-11-16T13:40:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/\"},\"wordCount\":712,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/\",\"name\":\"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=\",\"datePublished\":\"2026-11-16T13:40:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - Market Newsdesk","og_description":"Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0 months, nearly doubled the 6.6 months observed in the SOC control group Favorable safety profile with no observed cytokine release syndrome (CRS), ICANS, major infections or treatment-related serious adverse events with up to six repeat doses of gamma-delta T cells NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated &hellip; Continue reading \"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T13:40:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy","datePublished":"2026-11-16T13:40:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/"},"wordCount":712,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/","name":"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=","datePublished":"2026-11-16T13:40:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODA3NyM3OTY3MTg5IzIxMjMwMDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-reports-updated-glioblastoma-data-at-sno-2026-demonstrating-median-overall-survival-of-20-9-months-and-50-two-year-survival-with-gamma-delta-t-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021277"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021277\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}